Ironwood Pharmaceuticals, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a IRWD research report →
Range $3.7 – $5.7
Price Chart
About the company
Ironwood Pharmaceuticals, Inc. operates as a healthcare enterprise primarily dedicated to discovering, developing, and commercializing therapeutic solutions for gastrointestinal (GI) conditions. Its flagship commercial product is linaclotide, a guanylate cyclase type-C (GC-C) agonist.
- CEO
- Thomas A. McCourt
- IPO
- 2010
- Employees
- 100
- HQ
- Boston, MA, US
Get TickerSpark's AI analysis on IRWD
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $778.09M
- P/E
- 5.11
- Fwd P/E
- 3.66
- PEG
- 0.01
- P/S
- 1.91
- P/B
- 0.00
- EV/EBITDA
- 2.67
- Div Yield
- 0.00%
- Gross Margin
- 99.89%
- Op Margin
- 62.84%
- Net Margin
- 37.38%
- ROE
- -93.40%
- ROIC
- 63.99%
Latest fiscal year · YoY change
- Revenue
- $296.15M-15.7%
- Gross Profit
- $296.15M-13.9%
- Op Income
- $118.76M
- Net Income
- $24.02M+2629.2%
- EPS
- $0.15+2627.3%
- OCF Growth
- +22.7%
- FCF Growth
- +22.8%
- 52W High
- $5.78
- 52W Low
- $2.95
- 50D MA
- $4.03
- 200D MA
- $3.96
- Beta
- 0.24
- RSI (14)
- 67
- Avg Volume
- 2.15M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Ironwood delivered a strong Q3 on LINZESS momentum, raised full-year guidance again, advanced apraglutide site activation, and continued deleveraging.· November 5, 2026
- Q3 LINZESS net sales were $325 million, helping drive a record quarter and prompting another raise to full-year U.S. net sales guidance of $1.2 billion-$1.25 billion.
- Total revenue was $133 million, GAAP net income was $60 million, and adjusted EBITDA was a record $98 million.
- Management said LINZESS demand has outperformed initial expectations, with mid-single-digit demand growth now expected for the full year and Q4 expected to be the strongest quarter.
- Apraglutide STARS-2 remains on track, with more than 100 planned sites across 22 countries and primary completion still estimated for October 2028.
- Debt reduction continues: Ironwood paid down $60 million of the revolver in the quarter and expects to end 2026 with less than $300 million of debt and gross leverage below 1X.
Total revenue was $133 million in Q3 2026. GAAP net income was $60 million and adjusted EBITDA was a record $98 million. LINZESS Q3 net sales were $325 million, and year-to-date net sales reached $880 million through Q3. Management said LINZESS demand was up 5% year over year, and full-year demand is still expected to grow in the mid-single digits. For full-year 2026, Ironwood raised LINZESS U.S. net sales guidance to $1.2 billion-$1.25 billion, total revenue guidance to $485 million-$510 million, and adjusted EBITDA guidance to greater than $350 million. The company also expects to end the year with less than $300 million of debt and gross leverage below 1X.
Tom McCourt framed Q3 as another step in a “turnaround year,” emphasizing execution across three priorities: maximizing LINZESS, advancing apraglutide, and delivering profits and cash flow. He said LINZESS is on its way back to blockbuster status and highlighted the durability of the brand in its 14th year. His tone was confident and upbeat, especially around the company’s ability to generate cash, reduce debt, and prepare for potential apraglutide commercialization.
Ron Silver highlighted the quarter’s financial strength: $133 million of total revenue, $60 million of GAAP net income, and a record $98 million of adjusted EBITDA. He said the company used cash on hand to pay down $60 million of the revolving credit facility, leaving $325 million outstanding at quarter end, with $86 million in cash and cash equivalents and $133 million in collaboration receivables. He also said the guidance raise reflects stronger LINZESS performance, with no meaningful changes to commercial margins and an implied 80% margin that management expects to continue through the rest of the year.
Analysts focused on whether LINZESS volume growth can persist once pricing tailwinds fade, and Tammi Gaskins said demand has exceeded early expectations and should remain strong, supported by broad access across channels and continued growth in the overall market. On pricing, management said the Medicare Part D Most Favored Nation price of $136 per month is in line with expectations and that they are working to optimize net price across channels. Questions also centered on margin and capital allocation; Ron Silver said there have been no meaningful commercial margin changes, while Gaskins said cash flows should support apraglutide development and launch, with shareholder returns and further deleveraging kept in view. On STARS-2, Jeff Silber said site activation is on track, primary completion is still expected in October 2028, and that should support an NDA submission in 2029.
The call showed clear operating momentum: LINZESS delivered a record quarter, management raised full-year guidance again, and demand growth appears to be holding up even after pricing changes. Ironwood is also generating strong cash flow, cutting debt, and maintaining enough financial flexibility to fund apraglutide development and a potential launch.
The biggest risk discussed was whether LINZESS demand can sustain once the current pricing benefits roll off, especially heading into 2027 and beyond. Apraglutide remains in a long clinical timeline, with primary completion not expected until October 2028 and an NDA only contemplated for 2029, so it is still some distance from potential commercialization.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 96.3%
- Shares Outstanding
- 165.55M
- Float Shares
- 159.40M
of shares held by institutions
220 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock, Inc. | 18.48M | ▲ 686.89K |
| Vanguard Group Inc | 15.96M | ▼ 113.81K |
| Armistice Capital, LLC | 13.93M | ▼ 1.10M |
| Sarissa Capital Management LP | 9.19M | 0 |
| Bank Of America Corp | 8.68M | ▲ 896 |
| Renaissance Technologies LLC | 8.04M | ▲ 48.57K |
| State Street Corp | 6.72M | ▼ 2.09M |
| Vanguard Capital Management LLC | 6.63M | ▲ 26.24K |
| Aqr Capital Management LLC | 6.47M | ▼ 1.07M |
| Vanguard Portfolio Management LLC | 5.06M | ▼ 449.55K |
| Acadian Asset Management LLC | 5.05M | ▼ 801.10K |
| Two Sigma Investments, LP | 4.56M | ▼ 1.29M |
Held by 216 ETFs
Biggest fund positions in IRWD by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 16, 26 | Gaskins Tammi L | sell | 5,919 |
| Sep 15, 26 | DENNER ALEXANDER J | other | 3,694 |
| Jul 20, 26 | Silber Jeffrey | other | 137,036 |
| Jul 20, 26 | Silber Jeffrey | other | 0 |
| Jul 7, 26 | Silver Ronald | sell | 127,890 |
| Jun 16, 26 | Shepard Jay | other | 63,481 |
| Jun 16, 26 | Kessler Marla L | other | 63,481 |
| Jun 16, 26 | Currie Mark G | other | 63,481 |
| Jun 16, 26 | Duane Jon R | other | 63,481 |
| Jun 16, 26 | DENNER ALEXANDER J | other | 63,481 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our IRWD coverage
Recent articles, reports, and earnings notes.
No research on IRWD yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate IRWD report →IRWD Q3 Earnings Beat, Revenues Miss, 2026 View Raised, Stock Up
zacks.com · Nov 6
Ironwood Pharmaceuticals, Inc. (IRWD) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 6
What Ironwood Pharmaceuticals (IRWD) Said on Its Q3 Earnings Call
marketbeat.com · Nov 5
Ironwood Pharmaceuticals (IRWD) Beats Q3 Earnings Estimates
zacks.com · Nov 5
Ironwood Pharmaceuticals Raises Full-Year 2026 Financial Guidance Driven by Continued LINZESS U.S. Net Sales Growth and Strong Third Quarter Financial Performance
businesswire.com · Nov 5
208,277 Ironwood Pharmaceuticals, Inc. $IRWD Shares Purchased by CWA Asset Management Group LLC
defenseworld.net · Oct 22
Ironwood Pharmaceuticals Appoints Tammi Gaskins as Chief Executive Officer
businesswire.com · Oct 16
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Stock Rated “Moderate Buy” by Sell-Side Brokerages
defenseworld.net · Oct 13
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.